Can CBD Help to Treat Glioblastoma Multiforme?
May 21st, 2019
App, Exclusive, News, Top News
Medical researchers are trying to play catchup after decades of prohibition from conducting research on cannabinoids. Early research suggests that cannabidiol (CBD), one of the most prevalent cannabinoids in the cannabis plant, could have numerous health benefits. CBD has been proposed or utilized as a treatment for epilepsy, PTSD, sleep disorders, inflammatory conditions, and side effects from chemotherapy – just to name a few. While there’s plenty of anecdotal evidence of success treating a wide range of medical conditions, researchers are still determining what’s really possible with CBD and robust clinical trials remain few and far between.
Cardiol Therapeutics Inc. (TSX: CRDL) (OTC: CRTPF) is a leader in the research and development of CBD-based pharmaceutical therapies and is diving headlong into the search for an effective treatment of glioblastoma multiforme (GBM). GBM is the most common form of malignant brain tumor and carries with it an average survival rate of less than one year. The disease has received its share of headlines as it led to the recent deaths of Sen. John McCain and Tragically Hip lead singer Gordon Downey. Cardiol is advancing a drug candidate, CRxIMT, that combines CBD with an immunotherapy-based approach for the treatment of GBM.
Anti-Tumor Properties of Cannabinoids
A small clinical study published in 2006 showed that 2 of 9 brain cancer patients demonstrated a decrease of tumor cell proliferation following administration of THC. Since then, a number of in vivo/in vitro studies have been conducted. All of the studies (35 in total) summarized in the linked review found that cannabinoids demonstrated anti-tumoral activity or anti-tumoral evidence. The effects range from slowing the rate of proliferation to killing cancer cells to limiting the metastatic spread of cancer.
Those wishing to dive deeper into the technical aspects and scientific descriptions of the studies are encouraged to investigate the links above. There is a lot of information with references to a number of studies. The upshot is that there is ample evidence of cannabinoids, especially CBD and THC, limiting the growth and spread of brain cancer. Another important takeaway – cannabinoids have been shown to be completely safe and to have no negative impact on healthy tissues. This is in stark contrast to the current standard of care, which includes a mix of surgery, radiation, and chemotherapy (none of which has been shown to be curative).
Cardiol Therapeutics is combining the anti-tumor effects of cannabinoids with the demonstrated potential of immunotherapy in its search for an effective GBM treatment. The company has developed a patent-pending cancer therapeutic platform based on this combined approach and is starting with GBM, while eyeing other forms of cancer for further research. GBM is an orphan indication, meaning that it is a rare and untreatable disease, and drug candidates for its treatment are eligible for assistance from the FDA’s Office of Orphan Products Development. The Office provides a grant program and tax incentives intended to help defray the costs of drug development for the treatment of rare diseases.
Cardiol believes the combination of immunotherapy and cannabinoids holds great promise. Cannabinoids may be able to decrease the immunosuppressive environment of a brain tumor, thereby improving the effectiveness of the tumor-killing actions of the immunotherapeutic regimen. The two approaches may work through different pathways to achieve a synergistic treatment that could be more effective than relying solely on either technique.
Cardiol’s Other Initiatives
Cardiol Therapeutics is simultaneously developing a number of potential treatments for heart failure, including one based on CBD. Heart failure is a leading cause of hospitalization, affecting more than 6 million people in the U.S. and Canada and costing more than $30 billion annually in the U.S. alone.
Cardiol utilizes a patented nanotherapeutic technology to deliver its active ingredients effectively and efficiently to the target tissue. The encapsulation hides the active lipophilic and hydrophobic (fat-loving and water-averse) ingredients in a hydrophilic shell, allowing cannabinoids and other similar pharmaceutical actives to circulate in the blood’s water-based environment. This technology potentially resolves many of the issues surrounding the bioavailability and deliverability of cannabinoid-based drugs.
Cardiol is also branching out into the world of medical cannabis treatments. In response to a pervasive and persistent shortage of CBD oil in the Canadian market, the company has near-term plans to launch its pharmaceutical CBD product across Canada. In essence, there is a huge spike in demand for CBD oil that took producers and provincial officials by surprise with no end in sight to the drastic shortage. According to Ray Gracewood, Chief Commercial Officer for OrganiGram, “The reality of the production environment is that cannabis takes a certain amount of time to grow within our facility and therefore it takes us some time to adapt to changes within forecasting.” OrganiGram is a Licensed Producer that is one of a very few that are currently able to provide CBD oil, according to the linked CBC article.
Cardiol does not rely on the cultivation of cannabis or hemp for its pharmaceutical ultra-pure CBD oil. Rather, the company has partnered with large-scale pharmaceutical manufacturers Dalton Pharma Services and Noramco, Inc. to synthesize CBD oil on an industrial scale. The opportunity is large, and Cardiol appears ready to meet the challenge.
Cardiol also brought on Thomas Moffatt as Chief Commercial Officer to lead the rollout. Mr. Moffatt is an experienced senior executive with 20 years served at Shoppers Drug Mart, Canada’s leading drug store retailer. Most recently, he was Chief Operating Officer at Rx Drug Mart. His experience will play a central role in the success of Cardiol’s ambitious pharmaceutical CBD plans.
Altogether, Cardiol Therapeutics offers an intriguing opportunity at the intersection of cannabinoid technology and pharmaceutical development. Combining the long-term promise of cannabinoid drugs with the shorter-term revenue potential of CBD sales, the company is uniquely positioned in the burgeoning field of cannabis science.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.